Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 5 / ACCORD 17: FOLFOX vs 5FU-Cisplatin in Inoperable Esophageal Cancer
NCT00861094Phase 3Completed
- Sponsor
- Unicancer
- Start
- Mar 2008
- Primary completion
- Sep 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in esophageal cancer (2 arms), sponsored by Unicancer. Primary endpoints: Percentage of patients who complete the full study treatment at 12 weeks, Endoscopic complete response rate at 12 weeks and 1 more. Started Mar 2008; status: completed.
02
Drugs
oxaliplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00861094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861094.